|
Renal Organic Solute Transporters: Relation to Serum |
|---|---|
| รหัสดีโอไอ | |
| Creator | Naohiko Anzai |
| Title | Renal Organic Solute Transporters: Relation to Serum |
| Contributor | Promsuk Jutabha, Hitoshi Endou |
| Publisher | Faculty of Pharmaceutical Sciences KKU MSU UBU |
| Publication Year | 2553 |
| Journal Title | Isan Journal ofPharmaceutical Sciences |
| Journal Vol. | 6 |
| Journal No. | 1 |
| Page no. | 1-14 |
| Keyword | Urate, Transporter, Hypouricemia, Hyperuricemia, Gout, PDZ |
| URL Website | https://tci-thaijo.org/index.php/IJPS |
| Website title | Isan Journal ofPharmaceutical Sciences, IJPS |
| ISSN | 19050852 |
| Abstract | Hyperuricemia is associated with an increased risk of developing gout, hypertension, cardiovasculardiseases such as myocardial infarction and stroke, and renal diseases such as acute urate nephropathyand nephrolithiasis, despite its beneficial role, e.g. antioxidative activity. The urate transport system of thekidney is an important determinant of the serum urate level, but clarification of its molecular mechanismremains incomplete. In 2002, our group identified URAT1, a kidney-specific urate transporter, leading tothe accumulation of information concerning individual molecules involved in urate transport in the kidney.In 2008, we functionally characterized facilitatory glucose transporter family member GLUT9 as avoltage-driven urate efflux transporter URATv1 and analysis of a renal hypouricemia patient with agenetic defect in URATv1/GLUT9 gene SLC2A9 have established the main route of the uratereabsorption pathway, where urate in the urinary lumen is taken up via URAT1 and intracellular urate exitsfrom the cell to the interstitium/blood space via GLUT9. Therapeutics designed to modify urate transportactivities of these proteins might be useful in treating pathologies associated with hyperuricemia. In thisreview, recent findings concerning these molecules are presented. |
